corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 5695

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Organon claims Tolvon has “similar levels of efficacy as amitripyline, imipramine and clomipramine, but is associated with significantly less side-effects” and is “similar in efficacy and side-effects to the newer anti-depressants with which it has been compared”
MaLAM Australian News 1993 Sep


Abstract:

Organon promotes Tolvon (mianserin) as being as effective as tricyclic antidepressants and newer antidepressants and safer than the tricyclics. These claims are not necessarily substantiated by the scientific literature.

Keywords:
*analysis/Australia/developed countries/mianserin/Tolvon/Organon/safety & risk information/efficacy/ psychotropic drugs/MaLAM/Medical Lobby for Appropriate Marketing/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES/PROMOTION IN SPECIFIC THERAPEUTIC AREAS: PSYCHIATRIC DISEASES

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society’s public-health interests…
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, Médecins Sans Frontières and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.